EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma

Lara Planas-Paz iD, Alicia Pliego-Mendieta iD, Catherine Hagedorn iD, Domingo Aguilera-Garcia iD, Martina Haberecker iD, Fabian Arnold iD, Marius Herzog iD, Lorenz Bankel iD, Roman Guggenberger iD, Sabrina Steiner, Yanjiang Chen, Abdullah Kahraman iD und 5 weitere

EMBO Molecular Medicine · 11.04.2023 · 15 (4)

DOI: 10.15252/emmm.202216863 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EMBO Molecular Medicine, online erschienen am 13.02.2023. Verfasst von Lara Planas-Paz und 16 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Systems Pathology and Functional Tumor Pathology, Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich,…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Sarcoma, Osteosarcoma, Bone Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Olga Mayenfisch Stiftung (Olga Mayenfisch Foundation), Swiss Cancer Foundation (SCF), University Hospital Zurich.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Defects in homologous recombination repair (HRR) in tumors correlate with poor prognosis and metastases development. Determining HRR deficiency (HRD) is of major clinical relevance as it is associated with therapeutic vulnerabilities and remains poorly investigated in sarcoma. Here, we show that specific sarcoma entities exhibit high levels of genomic instability signatures and molecular alterations in HRR genes, while harboring a complex pattern of chromosomal instability. Furthermore, sarcomas carrying HRD ness traits exhibit a distinct SARC‐HRD transcriptional signature that predicts PARP inhibitor sensitivity in patient‐derived sarcoma cells. Concomitantly, HRD high sarcoma cells lack RAD51 nuclear foci formation upon DNA damage, further evidencing defects in HRR. We further identify the WEE1 kinase as a therapeutic vulnerability for sarcomas with HRD ness and demonstrate the clinical benefit of combining DNA damaging agents and inhibitors of DNA repair pathways ex vivo and in the clinic. In summary, we provide a personalized oncological approach to treat sarcoma patients successfully.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsSarcomaOsteosarcomaBone NeoplasmsHumansRecombinational DNA RepairPoly(ADP-ribose) Polymerase InhibitorsHomologous Recombination

Stichwörter der Autor:innen

HRD scoreHRDnessgenomic instabilitysarcoma

Substanzen

Antineoplastic AgentsPoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Laboratory for Systems Pathology and Functional Tumor Pathology, Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
  • Molecular Tumor Profiling Laboratory, Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
  • Department of Medical Oncology and Haematology, University Hospital Zurich, Zurich, Switzerland.
  • Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland.
  • Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Precision Oncology Laboratory, Department for Biomedical Research, Bern Center for Precision Medicine, Bern, Switzerland.

ORCID-Profile: Lara Planas-Paz, Alicia Pliego-Mendieta, Catherine Hagedorn, Domingo Aguilera-Garcia, Martina Haberecker, Fabian Arnold, Marius Herzog, Lorenz Bankel, Roman Guggenberger, Abdullah Kahraman, Martin Zoche, Holger Moch, Christian Britschgi, Chantal Pauli

Förderung

  • Olga Mayenfisch Stiftung (Olga Mayenfisch Foundation)
  • Swiss Cancer Foundation (SCF)
  • University Hospital Zurich

Zitieren

APA

Planas-Paz, L., Pliego-Mendieta, A., Hagedorn, C., Aguilera-Garcia, D., Haberecker, M., Arnold, F., Herzog, M., Bankel, L., Guggenberger, R., Steiner, S., Chen, Y., Kahraman, A., Zoche, M., Rubin, M. A., Moch, H., Britschgi, C., & Pauli, C. (2023). Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma. EMBO Molecular Medicine, 15(4). https://doi.org/10.15252/emmm.202216863

Vancouver

Planas-Paz L, Pliego-Mendieta A, Hagedorn C, Aguilera-Garcia D, Haberecker M, Arnold F, et al. Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma. EMBO Molecular Medicine. 2023;15(4). doi:10.15252/emmm.202216863

BibTeX
@article{PlanasPaz2023,
  author = {Planas-Paz, Lara and Pliego-Mendieta, Alicia and Hagedorn, Catherine and Aguilera-Garcia, Domingo and Haberecker, Martina and Arnold, Fabian and Herzog, Marius and Bankel, Lorenz and Guggenberger, Roman and Steiner, Sabrina and Chen, Yanjiang and Kahraman, Abdullah and Zoche, Martin and Rubin, Mark A and Moch, Holger and Britschgi, Christian and Pauli, Chantal},
  title = {Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma},
  journal = {EMBO Molecular Medicine},
  year = {2023},
  volume = {15},
  number = {4},
  doi = {10.15252/emmm.202216863}
}
Kostenlos starten →